 SAN DIEGO, Oct. 06, 2021 GLOBE NEWSWIRE -- Progenity, Inc. Progenity Nasdaq: PROG, an innovative biotechnology company, today announced the closing of its previously announced registered direct offering of 13,333,334 shares of the Companys common stock, at a purchase price of 1.50 per share, priced at a premium to market under Nasdaq rules for gross proceeds of approximately 20 million, before deducting the placement agents fees and other offering expenses. 